Monitoring-based antibiotic dose optimisation
Therapeutic drug monitoring (TDM)-based dose adjustment of piperacillin/tazobactam and meropenem is associated with improved antibiotic exposure in critically ill patients with normal renal function. Level of evidence: 1B (CEBM, RCT of good quality) Lead author: Jan J De Waele, Jan.dewaele@ugent.be
Three-part clinical question:
Patients: Critical care patients with normal renal function who were receiving piperacillin/tazobactam and/or meropenem. Intervention: Therapeutic drug monitoring (TDM)based dose adjustment of piperacillin/tazobactam and meropenem. Outcomes: The primary outcome was the percentage of time the plasma antibiotic concentration exceeded four times the minimum inhibitory concentration (MIC) of the causative organism (or if unknown, the MIC used was the epidemiological cut-off of wild-type Pseudomonas species of 16 mg/L for piperacillin/tazobactam and 2 mg/L for meropenem) during a dosing interval, over the first 72 h of treatment (% fT >4MIC ). The target was 100%.
Secondary outcomes were the percentage of time the plasma antibiotic concentration exceeded the MIC during a dosing interval over the first 72 h of treatment (% fT >MIC ) and absolute values for the fT >4MIC and fT >MIC . Clinical response was also evaluated at day 7. ICU, hospital and 28-day mortality were recorded. Control group: (20 patients) Antibiotics were delivered according to standard hospital extended infusion protocols (30 min loading infusion followed by infusion over 3 h). The infusion was then repeated at 6 hourly (piperacillin/tazobactam) or 8 hourly (meropenem) intervals. Antibiotic levels were taken at predefined times throughout the study.
Therapeutic drug monitoring dose adjustment group: (21 patients) As per control group except the dosing frequency (and dose for meropenem) was increased or decreased according to a pre-defined algorithm based on the actual antibiotic levels. . Significantly more patients achieved target antibiotic plasma levels in the intervention group. . The intervention significantly increased the median time the antibiotic levels were more than four times MIC (44.5% to 86% on day 2 and 60% to 90% on day 3; p ¼ 0.012). . There were no adverse events relating to antibiotics in either group.
EBM questions:
1. Do the methods allow accurate testing of the hypothesis? Yes. This study was well designed to detect whether dose adjustment (based on daily therapeutic drug monitoring) could achieve better pharmacokinetic target attainments than with standard dosing. It was a single-centre, prospective, partially blinded, randomised controlled trial. The main outcomes were blinded. Some of the secondary clinical outcomes (clinical response at day 7) were only partially blinded making observer bias unlikely; however, this does not weaken the main pharmacokinetic outcomes of the study. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes, although this is the first work of its kind and powering the study was impossible. 3. Are the conclusions valid in light of the results? Yes.
They are that:
. TDM-based dose adaptation of beta-lactam antibiotic therapy improves antibiotic exposure in critically ill patients with normal renal function. . Standard dosing does not achieve target concentrations in all patients even with conservative plasma targets. . Whether TDM-based dose adaptation leads to improved patient outcomes remains to be determined. 4. Did results get omitted and why? Yes.
. Three patients did not complete the study protocol and target attainment at day 3 could not be calculated for these patients.
5.
Did they suggest areas of future research? Yes. It suggests TDM could be studied in patients at risk of under-dosing (obese patients and patients on renal replacement therapy). The paper also acknowledges it was not powered to detect clinical outcome differences and this requires further study. 6. Did they make recommendations based on the results and were they appropriate? No. 7. Is the study relevant to my clinical practice? Yes.
The study shows many (up to 85%) patients with normal renal function may not be receiving adequate doses of piperacillin/tazobactam or meropenem. This could explain treatment failure on ICU and contribute to unnecessary morbidity and mortality; this may also add to selection pressures and compound antibiotic resistance. TDM is a strategy to address this shortfall in antibiotic delivery. 
